Risdiplam: A Small Molecule mRNA Splice Modifier Approved to Treat SMA Disease
Toxicologic Pathology · 2025-12 · 53 (8) · 695-699
DOI: 10.1177/01926233251392863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicologic Pathology, online erschienen am 18.11.2025. Verfasst von Lutz Müller und 2 weiteren Autor:innen. Beteiligte Einrichtung: F. Hoffmann-La Roche Ltd, Basel, Switzerland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
Risdiplam is the only approved small molecule mRNA splice modifier to date. Over more than five years since its first approval, thousands of patients with spinal muscular atrophy have benefited from risdiplam therapy. Yet, the nonclinical development of risdiplam was marked by toxicological challenges requiring new strategies and approaches, which ultimately translated into clinical success. This minireview covers key aspects of the nonclinical development of risdiplam, particularly focusing on its toxicological characterization and histopathological features in animal studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- F. Hoffmann-La Roche Ltd, Basel, Switzerland.
ORCID-Profile: Björn Jacobsen, Alexander Nürnberg
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Müller, L., Jacobsen, B., & Nürnberg, A. (2025). Risdiplam: A Small Molecule mRNA Splice Modifier Approved to Treat SMA Disease. Toxicologic Pathology, 53(8), 695-699. https://doi.org/10.1177/01926233251392863
Vancouver
Müller L, Jacobsen B, Nürnberg A. Risdiplam: A Small Molecule mRNA Splice Modifier Approved to Treat SMA Disease. Toxicologic Pathology. 2025;53(8):695-699. doi:10.1177/01926233251392863
BibTeX
@article{Mller2025,
author = {Müller, Lutz and Jacobsen, Björn and Nürnberg, Alexander},
title = {Risdiplam: A Small Molecule mRNA Splice Modifier Approved to Treat SMA Disease},
journal = {Toxicologic Pathology},
year = {2025},
volume = {53},
number = {8},
pages = {695--699},
doi = {10.1177/01926233251392863}
}
EUVIMED